Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
7.0
Journals
Antioxidants
Special Issues
Advances in Plant Antioxidants in Breast and Gastric Cancer Therapy
share announcement

Advances in Plant Antioxidants in Breast and Gastric Cancer Therapy

A special issue of Antioxidants (ISSN 2076-3921).

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2296

Special Issue Editor

Dr. Tae Woo Kim

E-Mail Website
Guest Editor
Department of Biopharmaceutical Engineering, Dongguk University-WISE, Gyeongju, Gyeongbuk 38066, Republic of Korea
Interests: ROS; calcium; ER stress; NOX; apoptosis; cell death; natural products; phytochemicals; plant antioxidants; cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Breast cancer is the most common cancer diagnosed in women and gastric cancer ranks as the second most common malignant disease. Chemotherapy and radiation therapy are the principal therapeutic approaches used for the treatment of breast and gastric cancer. There have been many studies on the treatment of breast and gastric cancer in the past few decades. However, resistance has been indicated as a major obstacle in therapy for breast and gastric cancer patients and acquired resistance is still unclear.

Hypoxia is known to be involved in chemoresistance and radioresistance. Understanding the chemoresistance and radioresistance mechanism would improve patient outcomes. Many strategies have been developed to overcome chemoresistance, radioresistance, and hypoxia resistance. Recently, to overcome these resistances in cancer therapy, therapeutic strategies using plant antioxidants have been suggested and challenged to overcome these resistances. Therefore, we suggest that plant antioxidants need to be investigated for their pathophysiological and molecular mechanisms of anti-cancer effects, such as apoptosis, cell death, necrosis, ER stress, necroptosis, cell cycle arrest, ROS, Ca2+, and autophagy in vitro and in vivo in resistant models.

This Special Issue of Antioxidants, “Advances in Plant Antioxidants in Breast and Gastric Cancer Therapy” will focus on the new advances in therapeutic strategies to overcome resistance in Breast and Gastric cancer therapy.

Dr. Tae Woo Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • gastric cancer
  • plant antioxidants
  • cancer therapy
  • hypoxia
  • chemotherapy
  • radiotherapy
  • resistance
  • apoptosis
  • cell death
  • ROS

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2068 KiB  
Article
Nodakenin Induces ROS-Dependent Apoptotic Cell Death and ER Stress in Radioresistant Breast Cancer
by Tae Woo Kim
Antioxidants 2023, 12(2), 492; https://doi.org/10.3390/antiox12020492 - 15 Feb 2023
Cited by 8 | Viewed by 1974
Abstract
Angelica gigas exerts powerful anti-tumor and anti-cancer effects in various cancer cell types. However, there have been few studies regarding the anti-cancer effect of nodakenin, a bioactive compound of Angelica gigas, in vivo and in vitro on breast cancers. I found that [...] Read more.
Angelica gigas exerts powerful anti-tumor and anti-cancer effects in various cancer cell types. However, there have been few studies regarding the anti-cancer effect of nodakenin, a bioactive compound of Angelica gigas, in vivo and in vitro on breast cancers. I found that nodakenin, in a concentration-dependent manner, inhibits breast cancer cell viability and decreases the tumor volume in mice. Additionally, nodakenin induces caspase-3-dependent apoptosis in breast cancer cells; however, the combination of Z-VAD-FMK and nodakenin suppresses the caspase-3-dependent apoptotic cell death. Furthermore, nodakenin mediates apoptotic cell death via the PERK-mediated signaling pathway and calcium (Ca2+) release, and nodakenin combined with thapsigargin induces synergistic cell death by inhibiting sarco/endoplasmic reticulum (ER) Ca2+-ATPase. However, knockdown of PERK or CHOP inhibits Ca2+ generation and caspase-dependent apoptosis in nodakenin-treated breast cancer cells. Nodakenin induces ROS and Ca2+ generation, ER stress, and apoptotic cell death; however, the knockdown of Nox4 inhibits ROS generation and ER stress- and caspase-dependent apoptotic cell death. In addition, nodakenin combined with radiation overcomes radioresistance in radioresistant breast cancer cells by suppressing epithelial–mesenchymal transition phenotypes, including the decrease in E-cadherin and the increase in N-cadherin and vimentin. Therefore, these findings indicate that nodakenin may be a novel therapeutic strategy for breast cancers. Full article
(This article belongs to the Special Issue Advances in Plant Antioxidants in Breast and Gastric Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop